Filing Flows › Intellia Therapeutics (NTLA) › Q2 2026
Intellia Therapeutics (NTLA) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Intellia Therapeutics (NTLA) reported revenue of $7.7M for the second quarter 2026 (Q2 2026), -46% from a year earlier and -49% from the quarter before.
Intellia Therapeutics, Q2 2026: revenue $7.7M (-46% year over year), net loss $107M, operating cash flow −$83.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.7M | -49% | -46% |
| Operating profit | −$113M | — | — |
| Net earnings | −$107M | — | — |
| Operating cash flow | −$83.1M | — | — |
What changed
Revenue was $7.7M in Q2 2026, down 46% year over year and down 49% from the previous quarter.
Operating costs exceeded revenue by $112.8M, an operating margin of -1472.3%. Total costs fell 3% while revenue fell 46%. The fastest-growing cost line was General & admin (+39%). The quarter ended with a net loss of $106.6M, wider than the previous quarter's $96.2M loss.
Operating cash flow was −$83.1M. Non-cash charges added back $2.1M of depreciation and amortization and $18.1M of share-based compensation. Capital expenditures of $1.8M exceeded it, leaving free cash flow of −$84.9M.
Questions
What was Intellia Therapeutics' revenue in the second quarter 2026?
Intellia Therapeutics (NTLA) reported revenue of $7.7M for the second quarter 2026 (Q2 2026), -46% from a year earlier and -49% from the quarter before.